This study suggests that PD-L1 could represent a useful prognostic marker for risk stratification in Middle Eastern PTC and that a PD-1/PD-L1 inhibitor could be a potential therapeutic option for aggressive PTC cancers, such as tall cell variant and BRAF mutation-positive patients that are unresponsive to standard PTC treatment. The gene discussed is BRAF; the disease is cancer.